H.C. Wainwright raised the firm’s price target on Microbot Medical (MBOT) to $9 from $7 and keeps a Buy rating on the shares. The firm believes Liberty could outcompete large and expensive capital equipment while reducing radiation exposure as well as physical strain for healthcare providers.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBOT: